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Editorial 
The importance of inflammation in early asthma 
Since the 1960s epithelial shedding and influx of 
eosinophils into the airway mucosa have been 
associated with asthma (1, 2). In 1985, fresh biopsies 
were taken from eight asthmatics (two mild, three 
moderate and three severe) which all showed virtual 
destruction and shedding of the epithelium at the 
three airway levels studied (3). This was in contrast to 
perfectly intact epithelium found in a control subject. 
The most important observation was that epithelial 
changes and influx of inflammatory cells also existed 
in the two untreated patients who showed mild 
disease both clinically and functionally. 
The existence of severe inflammatory changes is 
well known from necropsy studies on patients who 
died of asthma. But is significant inflammation also 
present in early asthma in patients with only a short 
duration of symptoms, or with mild disease? Indeed, 
this has been confirmed at the histological level by 
investigating biopsy samples obtained by bronchos- 
copy (4-6). What is the clinical importance of these 
findings? Should patients with asthma be treated with 
anti-inflammatory medication from the very begin- 
ning of therapy? The answer is yes (78) and control- 
ling the inflammatory process also seems to modify 
the outcome of the disease (9). 
For decades asthma has been defined in functional 
terms: it is a disease with variable airways obstruc- 
tion. A few years ago, a new attempt to define asthma 
was introduced: asthma is a chronic inflammatory 
disorder of the airways in which many cells play a 
role . this inflammation causes symptoms which 
are usually associated with widespread but variable 
airflow obstruction . . . (10). It is now obvious that 
the virtually persistent inflammatory process in the 
airway wall, with associated vasodilatation, oedema 
and epithelial damage, plays a fundamental role in 
most, if not in all, patients with asthma. But what is 
not obvious is the relation of this inflammation to the 
disturbances of lung function, and specifically to 
increased bronchial responsiveness. Transient eosino- 
philic inflammation of the bronchial mucosa may be 
quite common, particularly in atopic subjects, but it 
does not always cause the clinical syndrome which we 
call asthma. The trigger for the airways to react with 
bronchial obstruction in one patient but not in 
another is also unknown. 
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Prolonged mucus production and cough, and 
occasional wheezing are clinical markers of the 
inflammatory reaction of the mucosa. It is probable 
that measurable disturbances of lung function indi- 
cate that the process has been going on for some 
time. It may be argued that when clinical asthma 
with increased bronchial responsiveness is detected, 
the diagnosis is always late. However, the time 
schedule for development of increased bronchial 
responsiveness is not known. 
The occurrence of asthma in various populations 
differs widely and reliable comparisons have been 
difficult, mainly because of the problems in defini- 
tions. Comparisons will be even more difficult with 
the new definition of asthma, which describes asthma 
not only in functional but also in pathophysiological 
and even morphological terms. The whole concept of 
asthma may face a new era, causing headaches for 
epidemiologists but meaning good news for those 
who are at risk of this disease. The eosinophilic 
inflammation (bronchitis) is detected at earlier stages, 
even before functional deterioration is observed. 
Consequently, treatment to control the inflammation 
is initiated, which should influence the outcome, and 
may even prevent overt asthma in the patient. 
Today, most patients with prolonged mucus pro- 
duction and cough, but with normal lung function, are 
treated with antibiotics, expectorants, antitussives, 
antihistamines, &agonists, anti-cholinergics and with 
everything else but adequate anti-inflammatory medi- 
cation. This is understandable because of the lack of 
handy diagnostic methods, bronchoscopy is not such a 
method! However, new biochemical methods are 
emerging from the intensive research of the mucosal 
inflammatory process, and the asthma ‘sedimentation 
rate’ may be on reach. To my mind, sputum (induced 
or spontaneous) is one key. 
It is important to realize that those subjects who 
show disturbed lung function (real asthmatics), are 
only part of the population with the problem of 
recurring eosinophilic airway inflammation. A name 
should exist for those who are in the circle but do not 
yet deserve the title of asthma for their condition. Are 
they having asthma-like symptoms? In the Finnish 
Asthma Programme (1 I), it was estimated that 5% of 
the Finnish population have asthma, and another 
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Fig. I Asthma and asthma-like symptoms as estimated in 
the Finnish population (11). 
10% experience occasional asthma-like symptoms 
(Fig. 1). We are convinced that a widened view of 
asthma would improve early detection of symptoms 
and lead to the correct type of interventions. Whether 
this approach has any impact on asthma severity 
remains to be seen. Nevertheless, the need for days in 
hospital because of asthma in Finland has already 
started to decline: from 200 000 days in 1985 to 
100 000 in the early 1990s. 
Inflammation is a response. What is the cause of 
the response leading to asthma, what is triggering it 
and how? These are the crucial questions to which 
answers should be searched for, especially in the 
affluent part of the world where asthma and asthma- 
like symptoms are clearly increasing. 
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